Allergan 8-K Results of Operations and Financial Condition

Exhibit 99.1

The following table represents the US Specialized Therapeutic segment product revenues of Allergan plc for the three months ended March 31, 2015, June 30, 2015, September 30, 2015, December 31, 2015, March 31, 2016 and June 30, 2016 ($ in millions):

	Three Months Ended March 31, 2015		Three Months Ended June 30, 2015		Three Months Ended September 30, 2015		Three Months Ended December 31, 2015		Three Months Ended March 31, 2016		Three Months Ended June 30, 2016
Total Eye Care	$	94.7	$	578.6	$	539.9	$	618.1	$	533.0	$	636.1
Restasis®		28.7		309.9		312.8		348.2		298.7		371.3
Lumigan®/Ganfort®		8.1		86.1		71.7		94.8		81.5		80.6
Alphagan®/Combigan®		10.1		93.4		81.4		100.1		84.9		96.0
Ozurdex®		2.7		16.6		17.6		19.2		19.4		21.5
Eye Drops		37.5		49.0		45.3		45.2		40.8		49.1
Other Eye Care		7.6		23.6		11.1		10.6		7.7		17.6
Total Medical Aesthetics		55.1		366.2		340.1		383.6		373.9		419.8
Facial Aesthetics		35.2		263.7		249.0		269.9		279.4		320.2
Botox® Cosmetics		22.4		159.5		159.3		169.0		165.4		189.9
Fillers		12.8		104.2		89.7		97.7		102.7		117.6
Kybella®		—		—		—		3.2		11.3		12.7
Plastic Surgery		14.1		54.1		54.3		64.9		48.1		52.8
Breast Implants		11.7		50.2		50.9		62.2		46.4		51.7
Other Plastic Surgery		2.4		3.9		3.4		2.7		1.7		1.1
Skin Care		5.8		48.4		36.8		48.8		46.4		46.8
SkinMedica®		3.1		25.5		23.0		25.0		26.6		29.1
Latisse®		2.7		22.9		13.8		23.8		19.8		17.7
Total Medical Dermatology		20.9		120.7		107.8		106.5		69.0		97.1
Aczone®		6.0		60.3		48.0		56.5		33.0		54.1
Tazorac®		12.6		25.5		27.6		26.6		17.1		23.4
Botox® Hyperhidrosis		2.1		18.4		15.0		17.0		16.3		16.3
Other Medical Dermatology		0.2		16.5		17.2		6.4		2.6		3.3
Total Neuroscience & Urology		68.1		277.7		291.4		301.7		306.8		326.3
Botox® Therapeutics		36.2		252.2		261.3		274.0		273.8		296.0
Rapaflo®		31.9		25.5		30.1		27.7		33.0		29.4
Other Neuroscience & Urology		—		—		—		—		—		0.9
Other		6.5		4.5		17.4		10.3		16.0		9.6
Total US Specialized Therapeutics	$	245.3	$	1,347.7	$	1,296.6	$	1,420.2	$	1,298.7	$	1,488.9

The following table represents the US General Medicine segment product revenues of Allergan plc for the three months ended March 31, 2015, June 30, 2015, September 30, 2015, December 31, 2015, March 31, 2016 and June 30, 2016 ($ in millions):

	Three Months Ended March 31, 2015		Three Months Ended June 30, 2015		Three Months Ended September 30, 2015		Three Months Ended December 31, 2015		Three Months Ended March 31, 2016		Three Months Ended June 30, 2016
Total CNS	$	517.6	$	560.8	$	406.7	$	356.0	$	321.6	$	317.5
Namenda XR®		150.6		204.7		214.5		189.5		173.1		166.5
Namenda® IR		245.4		232.6		54.9		23.4		5.8		4.1
Namzaric®		—		1.6		1.7		7.9		10.3		12.8
Viibryd®/Fetzima®		79.6		80.7		84.5		82.8		83.3		81.7
Vraylar™		—		—		—		—		7.6		11.1
Saphris®		42.0		41.2		51.1		52.4		41.5		41.3
Total Gastroenterology(GI)		366.6		373.2		398.6		436.9		403.6		442.0
Linzess®		95.5		112.1		117.5		129.7		137.1		150.5
Viberzi®		—		—		—		12.3		4.0		20.4
Asacol®/Delzicol®		131.9		134.0		141.9		145.1		105.9		119.8
Carafate®/Sulcrate®		53.6		46.9		52.9		59.7		61.0		50.3
Canasa®/Salofalk®		33.0		34.6		34.6		34.9		41.1		46.7
Zenpep®		41.3		37.1		43.1		45.9		49.6		43.0
Other GI		11.3		8.5		8.6		9.3		4.9		11.3
Total Women’s Health		229.3		219.4		268.0		281.3		263.7		296.1
Lo Loestrin®		82.7		79.2		89.8		94.8		89.3		101.0
Minastrin® 24		64.8		56.1		74.4		77.1		79.6		83.0
Estrace® Cream		71.9		70.1		87.4		96.8		80.6		97.2
Liletta®		—		4.9		5.8		4.1		4.9		5.7
Other Women’s Health		9.9		9.1		10.6		8.5		9.3		9.2
Total Anti-Infectives		41.9		44.1		52.3		50.5		51.5		63.1
Teflaro®		37.8		31.7		35.8		32.3		33.4		35.2
Avycaz®		—		5.4		7.5		9.7		8.4		13.7
Dalvance®		1.9		4.5		4.9		5.5		6.2		10.2
Other Anti-Infectives		2.2		2.5		4.1		3.0		3.5		4.0
Other		488.3		410.5		426.4		410.0		413.3		330.4
Bystolic®		163.7		157.1		155.3		168.7		163.6		150.3
Armour Thyroid		29.0		25.2		34.7		41.9		42.1		40.6
Enablex®		16.3		18.0		17.2		17.7		12.8		—
Lexapro®		19.5		16.3		17.8		18.0		18.7		16.5
Savella®		23.8		27.8		29.0		25.8		23.7		22.3
PacPharma		3.0		26.2		27.4		25.5		28.8		14.7
Other		233.0		139.9		145.0		112.4		123.6		86.0
Total US General Medicine	$	1,643.7	$	1,608.0	$	1,552.0	$	1,534.7	$	1,453.7	$	1,449.1

The following table represents the International segment product revenues of Allergan plc for the three months ended March 31, 2015, June 30, 2015, September 30, 2015, December 31, 2015, March 31, 2016 and June 30, 2016 ($ in millions):

	Three Months Ended March 31, 2015		Three Months Ended June 30, 2015		Three Months Ended September 30, 2015		Three Months Ended December 31, 2015		Three Months Ended March 31, 2016		Three Months Ended June 30, 2016
Total Eye Care	$	40.5	$	301.7	$	281.5	$	295.0	$	291.5	$	318.7
Lumigan®/Ganfort®		13.1		90.4		86.2		93.7		88.1		94.5
Alphagan®/Combigan®		5.9		42.1		39.4		38.7		41.8		44.2
Ozurdex®		4.3		34.4		34.0		39.6		41.1		45.7
Optive®		3.3		25.4		23.2		25.0		24.1		26.0
Restasis®		1.2		15.1		15.5		16.4		15.0		19.3
Other Eye Drops		6.3		49.2		44.0		44.2		43.1		46.0
Other Eye Care		6.4		45.1		39.2		37.4		38.3		43.0
Total Medical Aesthetics		32.9		262.2		214.8		246.4		244.9		284.1
Facial Aesthetics		24.7		215.2		176.5		203.4		205.5		240.6
Botox® Cosmetics		12.9		123.4		98.6		115.4		104.9		132.7
Fillers		11.8		91.8		77.9		88.0		100.1		107.3
Belkyra® (Kybella®)		—		—		—		—		0.5		0.6
Plastic Surgery		7.8		43.2		34.6		40.0		36.8		40.3
Breast Implants		7.8		43.2		34.6		39.9		36.7		40.2
Earfold™		—		—		—		0.1		0.1		0.1
Skin Care		0.4		3.8		3.7		3.0		2.6		3.2
Other		45.3		153.2		164.3		149.5		136.9		154.2
Botox® Therapeutics		10.4		77.9		70.2		75.6		77.1		84.8
Asacol®/Delzicol® (GI)		17.2		15.3		15.3		17.7		15.3		11.0
Constella® (GI)		0.7		1.1		1.1		1.6		3.8		4.6
Other Products		17.0		58.9		77.7		54.6		40.7		53.8
Total International	$	118.7	$	717.1	$	660.6	$	690.9	$	673.3	$	757.0